INTERACTIONS BETWEEN CALCIUM-CHANNEL BLOCKERS AND ALPHA-ADRENOCEPTORS IN THE HUMAN CORONARY AND MAMMARY ARTERIES - A RADIOLIGAND BINDING STUDY

被引:5
作者
BRONZETTI, E
FELICI, L
POLIDORI, C
AMENTA, F
机构
[1] UNIV CAMERINO,IST FARMACOL,SEZ ANAT UMANA,I-62032 CAMERINO,ITALY
[2] UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI CARDIOVASC & RESP,ROME,ITALY
来源
JOURNAL OF AUTONOMIC PHARMACOLOGY | 1994年 / 14卷 / 02期
关键词
D O I
10.1111/j.1474-8673.1994.tb00592.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
1 The study was designed to assess whether Ca2+ channel blockers of the dihydropyridine family (felodipine, nicardipine, nifedipine, nimodipine, nitrendepine and nisoldipine), and of the phenylalkylamine family (verapamil) have any effect on alpha-adrenoceptor binding to sections of the human right coronary and mammary arteries, measured using [H-3]-dihydroergocryptine (DHT) as a ligand. 2 Increasing concentrations of nicardipine, verapamil and nitrendepine competed with [H-3]-DHT binding to sections of the human coronary and mammary arteries. The other compounds tested were without effect. Among the competitors of [H-3]-DHT binding, nicardipine was the most powerful, with a 50% inhibition (IC50) value of approximately 10 nM. 3 The pharmacological profile of competition with [H-3]-DHT binding by nicardipine, in the presence or in the absence of guanosine triphosphate and NaCl, is consistent with antagonist activity of the dihydropyridine derivative at the alpha-adrenoceptor. 4 This property may account for the lower sympathetic stimulatory activity elicited by nicardipine, in comparison with other Ca2+ channel blockers used in cardiovascular therapy.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 17 条
[1]   AUTORADIOGRAPHIC LOCALIZATION OF BETA-ADRENERGIC RECEPTORS IN HUMAN LARGE CORONARY-ARTERIES [J].
AMENTA, F ;
COPPOLA, L ;
GALLO, P ;
FERRANTE, F ;
FORLANI, A ;
MONOPOLI, A ;
NAPOLEONE, P .
CIRCULATION RESEARCH, 1991, 68 (06) :1591-1599
[2]  
BEVILACQUA M, 1991, CARDIOVASC RES, V4, P290
[3]   POSTSYNAPTIC ALPHA-1-ADRENERGIC AND ALPHA-2-ADRENERGIC MECHANISMS IN CORONARY VASOCONSTRICTION [J].
CHEN, DG ;
DAI, XZ ;
ZIMMERMAN, BG ;
BACHE, RJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1988, 11 (01) :61-67
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]  
ELMFELDT D, 1987, CAN J PHYSL PHARM, V10, pS154
[6]  
FLECKENSTEIN A, 1983, CIRC RES, V52, P13
[7]   ASSESSMENT OF QUALITY-OF-LIFE IN CARDIOVASCULAR THERAPY [J].
FLETCHER, AE ;
BULPITT, CJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 :S173-S181
[8]  
GARTHOFF B, 1987, CAN J PHYSL PHARM, V9, pS8
[9]   ACUTE EFFECTS OF THE CALCIUM-ANTAGONIST, NIFEDIPINE, ON BLOOD-PRESSURE, PULSE-RATE, AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].
HIRAMATSU, K ;
YAMAGISHI, F ;
KUBOTA, T ;
YAMADA, T .
AMERICAN HEART JOURNAL, 1982, 104 (06) :1346-1350
[10]  
LIMBIRD LE, 1982, MOL PHARMACOL, V21, P609